BioCentury | Aug 25, 2020

Politics & plasma: a BioCentury podcast

Ex-FDA officials are mixed on the merits of an agency decision to grant an EUA for COVID-19 convalescent plasma, but there is widespread agreement that the process was marred by political posturing, including statements by...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Aug 9, 2018
Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary...
BioCentury | Feb 24, 2015
Company News

Celltrion, Hospira avoid biosimilar traffic jam in U.S.

With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks to an amended deal that gives Hospira exclusive...
BioCentury | Oct 31, 2013
Targets & Mechanisms

KCC2 escape from neuropathic pain

A Canadian team has published preclinical proof of concept that activating a transporter called KCC2 represents a new mechanism for treating neuropathic pain. 1 The group expects that compounds against the ion transporter will be...
BioCentury | Feb 4, 2010
Tools & Techniques

Nanoparticle drug delivery heats up

Although there is broad consensus on the properties of a good therapeutic nanoparticle-the ability to concentrate a drug and release it slowly at a specific site-achieving such targeted delivery has remained elusive. Now, a pair...
BioCentury | Mar 19, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular F11 receptor (F11R; JAM-A) Studies in mice and in cell culture suggest that soluble JAM-A could be a...
BioCentury | Sep 22, 2008

Shaking in their shorts

Shaking in their shortsA handful of heavily shorted small cap biotechs got a bounce last week after the U.S. Securities and Exchange Commission announced new actions intended to eliminate "naked" short selling - the abusive practice...
BioCentury | Sep 4, 2008
Targets & Mechanisms

CXCR4 for CNS Infections

The purpose of the blood-brain barrier is to limit trafficking of leukocytes into the immune-privileged CNS. However, this becomes an undesirable trait when trying to clear acute CNS infections. 1 Indeed, one component of the...
Items per page:
1 - 10 of 26